z-logo
open-access-imgOpen Access
GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer
Author(s) -
Samantha M. Bevill,
José F. Olivares-Quintero,
Noah Sciaky,
Brian T. Golitz,
Darshan Singh,
Adriana S. Beltrán,
Naim U. Rashid,
Timothy J. Stuhlmiller,
Andrew Hale,
Nathaniel J. Moorman,
Charlene Santos,
Steven P. Angus,
Jon S. Zawistowski,
Gary L. Johnson
Publication year - 2019
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/kjen-ha42
Subject(s) - bromodomain , triple negative breast cancer , apoptosis , cancer research , breast cancer , cancer , bet inhibitor , chemistry , medicine , biology , epigenetics , biochemistry , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here